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MICROABSTRACT 
Long-term responders (LTR) are defined by at least 18 months of response to sunitinib 
in metastatic clear cell renal cell carcinoma (ccRC).  Well described by clinical studies, 
the phenotype of these tumours has never been explored. Primary tumour of LTR 
demonstrated a different phenotype with PD-L1 low expression suggesting a potentially 
lower impact of targeted immunotherapy in these patients. 
ABSTRACT  
Background: Long-term responders (LTR) are defined by at least 18 months of response to 
sunitinib in metastatic clear cell renal cell carcinoma (ccRCC).  Well described by clinical 
studies, the phenotype of these tumours has never ben explored. 
Patients and methods: In a retrospective and multicentre study, 90 ccRCC of metastatic 
patients were analysed. Immunohistochemistry (CAIX, VEGF, c-MET, PD-L1 and PD-1), 
VHL status were performed. Progression free survival (PFS) and overall survival (OS) were 
calculated from sunitinib introduction and from prog ession. LTR and their corresponding 
tumours were compared to others using univariate and multivariate analysis. 
Results: Twenty-eight patients were LTR. They had a median PFS of 28 versus (vs) 4 months 
for other patients (p<0.001). Similarly, LTR had a median OS of 49 vs 14 months (p<0.001), 
even from progression (median 21 vs 7 months, p=0.029) They were associated with a 
favourable or intermediate risk (IMDC model) (p=0.07) and less liver metastasis (p=0.036). 
They experienced more frequent complete or partial responses at the first radiologic 
evaluation (p=0.035). The corresponding ccRCC were associated with less nucleolar ISUP 
grade 4 (p=0.037) and hilar fat infiltration (p=0.06). They were also associated with low PD-
L1 expression (p=0.02). Only IMDC model and PD-L1 expression remained significant after 
multivariate analysis (p=0.014 and p=0.029, respectiv ly). 
Conclusion: Primary tumour characteristics of LTR were studied for the first time and 
demonstrated a different phenotype. Interestingly, they were characterized by low expression 
of PD-L1, suggesting a potentially lower impact of argeted immunotherapy in these patients.
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INTRODUCTION 
 
Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal 
cancer (70%).1 Along with hereditary ccRCC, sporadic ccRCC is also frequently 
characterized by an alteration of the VHL gene, a tumour suppressor gene, leading to the 
transcription of genes regulated by HIF such as VEGF, which triggers the angiogenic 
process.2 In 20% of patients, ccRCC is diagnosed at metastatic stage and 30% of the 
remaining patients will further develop metastases d tected during follow-up. With an 
approximately 50% risk of metastasis, the prognosis f ccRCC is poor, and the mortality rate 
is 40% at 5 years.3  
 
Anti-angiogenic therapies have significantly improved the prognosis of patients with 
metastatic clear cell renal cell carcinoma (ccRCC).4 Sunitinib, a tyrosine kinase inhibitor 
(TKI) targeting VEGFR, is currently an approved first-line treatment option for patients and is 
the most commonly administered treatment worldwide.5, 6 However, up to 30% patients 
experience progressive disease (PD) upon response evaluation criteria in solid tumours 
(RECIST) at their first evaluation and most patients ul imately develop PD.7 Although several 
resistance mechanisms have been described, few molecular markers of sensitivity or primary 
resistance with a prognostic impact have been identified.8   
 
Another treatment approach is based on targeted immunotherapy using checkpoint inhibitors 
because ccRCC is considered an immunogenic tumour with high numbers of mononuclear 
immune cells such as tumour-infiltrating lymphocytes (TIL).9-11 PD-L1 is a transmembrane 
protein which binds to its co-stimulatory receptor, PD-1 (B7-1), expressed by activated TILs, 
as a means to down-regulate antitumour immune responses by promoting TIL apoptosis and 
thus favour tumour progression. Recent clinical trial (Checkmate 025) demonstrated the 
superiority of anti-PD-1 (nivolumab) over everolimus in second-line treatment.12 Following 
the results of Checkmate 214, the combination of nivolumab plus ipilimumab is now 
recommended as first-line therapy for patients with in ermediate or poor prognosis according 
to International Metastatic Renal Cell Carcinoma Datab se Consortium (IMDC) model.13, 14 
  
Although numerous studies have focused on primary refractory patients defined by 
progression within the first 3 months, few have studied LTR.15 Molina et al. defined long-
term response as a durable complete response or remaining progression-free for more than 18 
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months and clinically characterized them without asses ing the phenotype of the tumours.16 
With the advent of new treatment in ccRCC, it is crucial to better identify them as these 
patients are the most likely to benefit from sunitinib.13  
 
In this study, we aimed to describe the pathological and immunohistochemical phenotype and 
VHL status of ccRCC and the clinical outcome of patients according to their long-term 
responder status.  
 
MATERIAL AND METHODS  
 
Patient selection and classification  
Primary ccRCC-specimens were collected from patients undergoing nephrectomy in two 
French University Hospitals (Rennes and Bordeaux) from 1997 to 2013 with metastases either 
at diagnosis or during the follow up. For inclusion in the study, patients with metastatic 
ccRCC received sunitinib (50mg/day, four weeks-on/two weeks-off) as first-line treatment 
(prior cytokine therapy was allowed) and completed at least one 28-day cycle of sunitinib, and 
undergone their first CTscan assessment with Response Evaluation Criteria In Solid Tumours 
(RECIST 1.1).17 Drug schedule and dose-reduction policy complied with local practice 
guidelines. Follow-up chest/abdomen CT-scans were pformed every 2 cycles of treatment 
(3 months). LTR were defined by at least 18 months of treatment without any progression.16 
For each patient, the following clinical and pathologic information was gathered (using data 
base UroCCR): age, sex, the six factors in the IMDC model (anaemia, thrombocytosis, 
neutrophilia, Karnofsky performance status <80, <1 year from diagnosis to first-line targeted 
therapy and hypercalcemia) before sunitinib introduction, pTNM stage at nephrectomy, 
tumour size, and nucleolar ISUP grade.18, 19 Histopathologic assessment was performed by 
three experienced pathologists (SFKJ, MY and NRL). For each patient, frozen ccRCC were 
available. Informed consent was signed from each patient and institutional review board 
approval was obtained for this study (CNIL declaration receipt 1812601v0). 
 
Immunohistochemical study  
For each primary tumour, a representative slide of the tumour with the highest nucleolar grade 
and the corresponding paraffin block was selected. Four µm-thick whole tissue sections were 
cut and mounted on glass slides (Superfrost+, Menzel Glazer). The preparations were dried 
for 1 hour at 58°C, and then overnight at 37°C. Thesections were deparaffinized with toluene 
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and rehydrated with ethanol. The preparations were pretreated and immunostained using 
Ventana Benchmark XT. VEGFA (Anti-VEGF antibody, sc-152, dilution 1/100 ; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), CAIX (Anti-CAIX antibody, ab15086, dilution 
1/1500, Abcam, Cambridge, UK), c-MET (Anti-Total c-MET, SP44, Rabbit Monoclonal 
Primary Antibody, ready-diluted, Ventana, Roche, Switzerland), PD-L1 (Anti-PD-L1 
antibody, clone 130021, dilution 1/200, RD System, Minneapolis, USA) and PD1 (anti-PD-1 
antibody, clone NAT105, dilution 1:50; Abcam, Cambridge, UK) expressions were assessed 
by immunohistochemistry as previously described.20-22 The reactivity of antibodies was 
revealed with HRP-labeled polymer conjugated secondary antibodies using diaminobenzidine 
(DAB) as chromogen (Sigma-Aldrich, France). Negative controls were performed by omitting 
the primary antibody. The tumour expression for each ntibody was independently evaluated 
(SFKJ and NRL), without knowledge of the case. The cut-off for positive cases was 30% of 
tumour cells for VEGF and 85% for CAIX as previously described.20, 21 For PD-L1 and MET, 
absent (0), weak (1), moderate (2) and strong expression (3) were reported and cases were 
then subdivided into negative (0–1) or positive (2–3) subgroups.22, 23 For PD-1, 
immunostaining density was evaluated in tumour infiltrating lymphocytes and was semi-
quantified as absent, rare, moderate or dense as previously reported.24  
 
VHL status  
Next generation sequencing  
For VHL gene, the entire coding sequence and exon-intron junctions of exons 1, 2 and 3 were 
analyzed. Genomic DNA was extracted using Magtration System 12GC (Bionobis) according 
to the manufacturer’s instruction. Genomic DNA from all samples was quantitated with the 
Quan-iT PicoGreen dsDNA assay kit (Thermo Fisher Scientific). DNA target preparation and 
enrichment were performed by amplification using the Access Array® system (Fluidigm, San 
Francisco, USA). A 10-nucleotide “barcode” tag, specific to each sample and Illumina-
specific sequencing adaptors were attached using secondary PCR. Purified products were then 
pooled and sequenced on the Illumina MiSeq NGS instrument (Illumina Inc., San Diego, 
California). 
Multiplex Ligation-dependent Probe Amplification  
Methylation-Specific-MLPA (MS-MLPA) was used to detec  CpG methylation islands in 
VHL gene promotor. The SALSA MS-MLPA kit ME001B Tumour suppressor-1 allows 
detecting aberrant methylation of CpG-Islands located in the promoter region of the VHL 
gene.25 The unmethylated DNA will not generate a signal, and  normal probe signal will be 
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detected if the site is methylated.  
 
Statistical analysis  
The phenotype of ccRCC (histologic and immunohistochemical features, VHL status in long 
term responders) was compared with other patients. As ociations were analyzed with χ², 
Fisher and Mann-Whitney tests. For logistic regression, we used a backward stepwise 
selection with p<0.05 inclusion criteria.  The rank of elimination was obtained when a 
variable was removed from the equation, and the odds ratio, 95% CI, and p-value for the 
removed variables were obtained on the removal step. For clinical outcome, we represented  
progression-free survival (PFS) from the sunitinib introduction to progression and overall 
survival (OS) from sunitinib introduction to death using Kaplan-Meier curves. We also 
represented PFS starting from 18 months for LTR and OS from progression to death. All p-
values were 2-sided, and p-values less than 0.05 were considered statistically significant. All 
statistical analyses were performed using Stata 14.1 (College Station, TX) software.  
  
RESULTS 
  
Patient and tumour characteristics  
Patient and tumour characteristics are presented in Table 1. The study retrospectively included 
90 consecutive metastatic patients with primary ccRCC. The mean follow-up period was 25 
months (range 1-76 months) from sunitinib introduction. The median PFS and OS were 10 
and 22 months, respectively. Eighty-five patients (94.4%) experienced progression and 71 
(78.9%) died from their cancer. Men were most represented (62.2% versus 37.8%). According 
to the IMDC model, most patients were in the intermdiate group (47.7%). Locally advanced 
tumours were mostly represented (stage pT3-T4 in 75.5% of patients), and showed a high 
nucleolar ISUP grade 3 or 4 (n=88, 92.3%). Metastase  were present at the initial diagnosis 
for 55.6% of patients. More than two-third of patien s presented multiple metastatic sites 
(n=69; 76.7%). The most common metastatic sites were lung (75.6%), bone (53.3%) and liver 
(23.3%).  
VHL status  
VHL status was assessed in the entire cohort (n=90). All patients were negative for germ-line 
mutations. A VHL gene mutation was observed in 64 cases (71.1%). Mutations occurred in 
exons 1, 2 and 3 in 28 (43.8%), 21 (32.8%) and 15 cases (23.4%) respectively. Stop, 
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frameshift, missense, and splice site mutations were d tected in 8 (12.5%), 34 (53.1%), 18 
(28.1%) and 4 (6.3%) cases respectively. VHL promoter methylation occurred in 10 cases 
(11.1%). At least one or more VHL abnormalities (VHL inactivation) were observed in 74 
cases (82.2%).   
Correlation with clinical outcome  
Twenty-eight patients were LTR and belonged to good (n=10), intermediate (n=15) and poor 
(n=3) risks according to IMDC score. Among LTR, 23 patients progressed and 13 received 
second-line therapy (everolimus, n=5; pazopanib, n=3; sorafenib, n=3; axitinib, n=2), 7 
received third-line therapy (everolimus, n=5; sorafenib, n=1 and axitinib, n=1) and 1 received 
a fourth-line therapy by pazopanib. Twelve patients were last known to be alive with a 
continuing response or stable disease. Kaplan Meier curves for PFS and OS are presented in 
Figures 1, 2 and 3. LTR had a median PFS of 28 months versus 4 months for other patients 
(p<0.001). Similarly, LTR had a median OS of 49 months versus 14 months for other patients 
(p<0.001). From progression, LTR still had a difference of survival, median OS of 21 versus 
7 months (p=0.29). 
Pathological, immunohistochemical phenotype and VHL status of LTR   
LTR had good or intermediate prognosis according to the IMDC model (p=0.007) and less 
liver metastasis (p=0.036) (Table 2). They more frequently experienced a complete or partial 
response at the first radiologic evaluation (p=0.035). Corresponding ccRCC were associated 
with less nucleolar ISUP grade 4 (p=0.037) and less hilar fat infiltration (p=0.006). They were 
also associated with low expression of PD-L1 by immunohistochemistry (p=0.02), Figure 4. 
No association with VHL status was identified. All the significant variables were included for 
logistic regression except liver metastases that could interfere with Heng score criteria. The 
only 2 factors that remained significantly associated with LTR were good or intermediate risk 
(IMDC model) (p=0.014, OR (95% CI)=5.29 (1.39, 20.01)) and low PD-L1 expression 
(p=0.029, OR (95% CI)=3.145 (1.22, 8.31)), Table 3.   
 
DISCUSSION 
 
To our knowledge, this is the first study to assess the phenotype of ccRCC in LTR along with 
a long term clinical follow-up. Previous studies identified clinic-biological criteria associated 
with LTR.  
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Molina et al. described for the first time the patients who benefit the most from sunitinib at 
clinical level 16. This retrospective study (n=186) mainly included ccRCC but also other 
subtypes representing 12% of their cohort even thoug  their carcinogenesis was different. 
Moreover, the majority of them (52.1%) received sunitinib in combination with gefitinib, 
bevacizumab or everolimus whose targets were not the same. In their study, favourable 
Memorial Sloan Kettering Cancer Center (MSKCC) score was associated with LTR. 
A recent study by Escudier et al. proposed a pooled analysis of clinical trials including 
retrospectively 5714 patients.26 Among them, 897 (15.7%) patients were LTR. They were 
associated with higher percentage of early tumour shrinkage at the first scan, white race, 
favourable criteria of IMDC mode, clear cell histology, no liver metastasis, body mass index 
≥ 25 kg/m². 
Similarly, in our study, LTR exhibited good or intermediate prognosis (IMDC model related 
to MSKCC), which remained unsurprisingly significant fter multivariate analysis. Moreover, 
they had significantly fewer liver metastases than other patients. Indeed, liver metastases were 
previously associated with poor prognosis in patients with metastatic ccRCC and the absence 
of liver metastases was already correlated to LTR.26, 27 McKay et al previously described that 
their impact was attributed to alteration of sunitinib metabolism and the liver 
microenvironment that could favour an aggressive phnotype.27  
One limitation of our study is the selection of 18 months as a cut-off to define LTR but was 
reproducible with previous studies.16, 26 Another limitation is our sample size impairing 
multivariate analysis. However, contrary to previous studies, we included only clear cell 
histology and performed a pathological and immunohist chemical study with VHL status on 
primary tumours along with clinical data. 
At molecular level, VHL was inactivated by mutually exclusive mutation or promoter 
methylation in the majority of cases without any association with the sunitinib response. As 
previously described, no association between VHL status and outcome was observed.28, 29 
VHL inactivation, considered as an archetypical tumour-initiating event in ccRCC 
carcinogenesis, failed to identify sunitinib responders, as other mechanisms probably 
interfere.  
We report a distinct pathological and immunohistochemical phenotype of the primary 
tumours of LTR. As a matter of fact, ccRCC were particularly associated with a lower 
nucleolar ISUP grade and a less frequent infiltration of hilar fat. They were independently 
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associated with lower expression of PD-L1 by immunohistochemistry. First demonstrated in 
our study, this is consistent with the results of Choueiri et al. who correlated PD-L1 
expression with poor outcome in patients with metasta ic ccRCC.30  
Recent update on metastatic ccRCC treatment based on recent Checkmate 214 results 
recommends a dichotomized approach for first line therapy according to IMDC model.13 In 
intermediate- and poor risk patients, targeted immunotherapies are now indicated whereas in 
favourable-risk patients, antiangiogenic therapy remains the standard of treatment. In our 
study, some LTR belonged to intermediate- and poor risk and could have been treated by 
immunotherapies according to the new standards; however, they clearly benefited from 
sunitinib. The high expression of PD-L1 associated with better response to immunotherapy in 
Checkmate 214 trial, could suggest, in LTR associated with low expression of PD-L1, less 
interest in targeted immunotherapies and reinforce its potential use as predictive biomarker. 
Interestingly, the OS was also found to be prolonged in these patients, even from progression. 
LTR demonstrated an increased overall survival that was not only explained by their response 
to sunitinib first-line treatment, but also to second-line targeted therapy. The hypothesis could 
be that these patients who are more than good responders to sunitinib may be likely to do well 
under other targeted therapy. Further studies could he p clarify whether such responses are 
specific to sunitinib or reflect underlying favourable biology.  
In conclusion, LTR showed a prolonged OS even from progression. Their primary tumours 
demonstrated a different phenotype with PD-L1 low expr ssion suggesting a potentially lower 
impact of targeted immunotherapy in these patients. 
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Tables 
 
Table 1: Patient and tumour characteristics of 90 metastatic ccRCC . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics No % 
Age (years)     
  Mean 61,3 
  Range 37-85 
Sexe       
  Male 56 62,2% 
  Female 34 37,8% 
IMDC     
  Favourable 20 22,2% 
  Intermediate 43 47,8% 
  Poor 27 30,0% 
T stage     
  T1 14 15,6% 
  T2 8 8,9% 
  T3 63 70,0% 
  T4 5 5,6% 
N stage     
  N0 75 83,3% 
  N1-N2 15 16,7% 
M stage     
  M0 40 44,4% 
  M1 50 55,6% 
Tumor size (cm)     
  Mean 9.6 
  Range 2-9.5 
ISUP nucleolar grade     
  Grade 2 7 7,8% 
  Grade 3 33 36,7% 
  Grade 4 50 55,6% 
RECIST 1   
Complete response 1 1,1% 
Partial response 27 30,0% 
Stable disease 34 37,8% 
  Progression disease 28 31,1% 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2: Comparison between long-term responders and other patients. 
 
Variables Long-term 
responders 
(n=28) 
% Other patients 
(n=62) 
% p-value 
Clinical and radiological data           
  Male 20 71,4% 36 58,1% 0,226 † 
  Age >65 8 28,6% 29 46,8% 0,104 † 
  Good/intermediate risk (IMDC) 25 89,3% 38 61,3% 0,007 † 
  Distant lymph node metastasis 11 39,3% 28 45,2% 0,603 † 
  Pulmonary metastasis 20 71,4% 48 77,4% 0,54 † 
  Bone metastasis 16 57,1% 32 51,6% 0,626 † 
  Liver metastasis 2 7,1% 19 30,6% 0,015 † 
  Cerebral metastasis 4 14,3% 15 24,2% 0,286 † 
  Multiple metastasis 21 75,0% 48 77,4% 0,802 † 
  RECIST 1 (CR-PR vs SD-PD) 13 46,4% 15 24,2% 0,035 † 
Pathological analysis         
  
Size >7cm 16 57,1% 42 67,7% 0,331 † 
Nucleolar ISUP grade 4 11 39,3% 39 62,9% 0,037 † 
Sarcomatoid component 3 10,7% 16 25,8% 0,104 † 
Tumor necrosis  19 67,9% 52 83,9% 0,085 † 
Microvascular invasion 11 39,3% 30 48,4% 0,422 † 
T3-T4 stage 19 67,9% 49 79,0% 0,253 † 
Hilar fat infiltration 7 25,0% 35 56,5% 0,006 † 
Peri-renal fat infiltration 14 50,0% 31 50,0% 1 † 
Venal invasion 14 50,0% 27 43,5% 0,569 † 
N1-N2 stage 3 10,7% 12 19,4% 0,375 ‡ 
M1 stage 15 53,6% 35 56,5% 0,799 † 
Immunohistochemistry       
  
CAIX  >85% 10 35,7% 18 29,0% 0,526 † 
VEGFA >30% 12 42,9% 38 61,3% 0,103 † 
MET 2-3 intensity 18 64,3% 44 71,0% 0,526 † 
PD-L1 2-3 intensity 16 57,1% 50 80,6% 0,02 † 
PD-1 moderate or dense 18 64,3% 48 77,4% 0,192 † 
VHL status        
  
  VHL mutation 20 71,4% 44 71,0% 0,964 † 
  Promoter methylation 2 7,1% 8 12,9% 0,718 ‡ 
  VHL inactivation 22 78,6% 52 83,9% 0,543 † 
 
†, χ² test; ‡, Fisher exact test 
RECIST 1: First RECIST evaluation, CR, complete response; PR, partial response; SD, stable 
disease; PD, progression disease 
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Table 3: Logistic regression with rank of elimination and intermediate results 
 
Variables Rank OR 95% CI p-value 
Good/intermediate prognosis (Heng) - 5.292 1.399, 20.01 0.014 
RECIST 1 (CR-PR vs SD-PD) 3 0.389 0.139, 1.083 0.071 
Nucleolar ISUP grade 4 1 0.509 0.182, 1.419 0.197 
Hilar fat infiltration 2 0.401 0.136, 1.184 0.098 
PD-L1 low intensity - 3.145 1.122, 8.812 0.029 
 
 
Supplementary table 
 
Variables Long-term responders 
(n=28) 
% Short-term responders 
(n=62) 
% p-value 
Heng score     
 
    
  Favourable 10 35,7% 10 16,1% 0.039 † 
  Intermediate 15 53,6% 28 45,2%  0.46 † 
  Poor 3 10,7% 24 38,7% 0,007 † 
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Figure 1: Kaplan Meier curve representing progression-free survival (PFS) and overall survival (OS) 
PFS: Median survival: 4 vs 28 months (p<0.001), OS: median survival: 14 vs 49 months (p<0.001)   
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Figure 2: Kaplan Meier curve representing progression free survival of long-term responders (n=28) with 
time zero starting at 18 months. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Kaplan Meier curves representing overall survival (OS) from progression. 
OS: median survival: 7 vs 21 months (p=0.029)   
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Figure 4:  PD-L1 expression 
A- Absence of PDL1 expression, immunohistochemistry (IHC) x100 
B- Low expression of PDL1, IHC x100 
C- Moderate expression of PDL1, IHC x100 
D- High expression of PDL1, IHC x100 
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Supplementary figure: Kaplan Meier curve representing progression-free survival (PFS) and overall 
survival (OS) according to PD-L1 intensity 
 PFS: Median survival: 8 vs 17 months (p=0.27), OS: Median survival: 18 vs 29 months (p=0.30) 
Low PDL1 intensity 
High PDL1 intensity 
Low PDL1 intensity 
High PDL1 intensity 
